Market capitalization | $120.71m |
Enterprise Value | $41.97m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.90 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-93.65m |
Free Cash Flow (TTM) Free Cash Flow | $-72.76m |
Cash position | $79.70m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a Immunic, Inc. forecast:
5 Analysts have issued a Immunic, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.11 -0.11 |
22%
22%
|
|
EBITDA | -94 -94 |
3%
3%
|
EBIT (Operating Income) EBIT | -94 -94 |
3%
3%
|
Net Profit | -95 -95 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Head office | United States |
CEO | Daniel Vitt |
Employees | 77 |
Founded | 2003 |
Website | imux.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.